At the top studied dose of 4.5 mg , cagrilintide produced a mean weight reduction of roughly 10.8% at 26 weeks , versus about 3.0% with placebo
Studies suggest its potential to promote neural growth factors, which could have implications for neuroprotection and neurodegenerative diseases such as Alzheimers
These include local irritation or redness at injection sites, mild headaches or dizziness, and occasional fatigue or nausea
So how do we, on a daily basis, boost our GLP-1, maintain our weight, maintain our glycemic index and more
doi:10.1001/jama.294.14.1799
The warning associated with these drugs is specifically for a very rare type called Medullary Thyroid Cancer